{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:08:40Z","timestamp":1782731320105,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100223"],"award-info":[{"award-number":["82100223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02036-x","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:03:52Z","timestamp":1741439032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"Ya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiYu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiChen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"1","key":"2036_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2036_CR2","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615\u201322.","journal-title":"Cancer Res"},{"issue":"8","key":"2036_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","volume":"130","author":"JL Harousseau","year":"2017","unstructured":"Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130(8):963\u201373.","journal-title":"Blood"},{"key":"2036_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015: 341430.","journal-title":"Biomed Res Int"},{"issue":"5","key":"2036_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30(5):1005\u201317.","journal-title":"Leukemia"},{"issue":"7182","key":"2036_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature06639","volume":"451","author":"N Mizushima","year":"2008","unstructured":"Mizushima N, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069\u201375.","journal-title":"Nature"},{"issue":"6","key":"2036_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.tranon.2018.08.014","volume":"11","author":"V Desantis","year":"2018","unstructured":"Desantis V, et al. Autophagy: a new mechanism of prosurvival and drug resistance in multiple myeloma. Transl Oncol. 2018;11(6):1350\u20137.","journal-title":"Transl Oncol"},{"issue":"9","key":"2036_CR8","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/cas.13711","volume":"109","author":"Y Lu","year":"2018","unstructured":"Lu Y, et al. Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. Cancer Sci. 2018;109(9):2706\u201316.","journal-title":"Cancer Sci"},{"issue":"6","key":"2036_CR9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332\u20136.","journal-title":"Blood"},{"issue":"5","key":"2036_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ijc.29078","volume":"136","author":"J Wen","year":"2015","unstructured":"Wen J, et al. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer. 2015;136(5):991\u20131002.","journal-title":"Int J Cancer"},{"issue":"1","key":"2036_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","volume":"68","author":"W Matsui","year":"2008","unstructured":"Matsui W, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190\u20137.","journal-title":"Cancer Res"},{"key":"2036_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.890891","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Profilin 1 induces tumor metastasis by promoting microvesicle secretion through the ROCK 1\/p-MLC pathway in non-small cell lung cancer. Front Pharmacol. 2022;13: 890891.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2036_CR13","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1073\/pnas.051515498","volume":"98","author":"W Witke","year":"2001","unstructured":"Witke W, et al. Profilin I is essential for cell survival and cell division in early mouse development. Proc Natl Acad Sci U S A. 2001;98(7):3832\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2036_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.32598\/bcn.12.2.1631.1","volume":"12","author":"M Nekouei","year":"2021","unstructured":"Nekouei M, et al. Mutant Profilin1 aggregation in amyotrophic lateral sclerosis: an in vivo biochemical analysis. Basic Clin Neurosci. 2021;12(2):213\u201322.","journal-title":"Basic Clin Neurosci"},{"issue":"16","key":"2036_CR15","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/onc.2013.166","volume":"33","author":"Z Ding","year":"2014","unstructured":"Ding Z, et al. Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene. 2014;33(16):2065\u201374.","journal-title":"Oncogene"},{"issue":"8","key":"2036_CR16","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3748\/wjg.v21.i8.2323","volume":"21","author":"YJ Cheng","year":"2015","unstructured":"Cheng YJ, et al. Silencing profilin-1 inhibits gastric cancer progression via integrin \u03b21\/focal adhesion kinase pathway modulation. World J Gastroenterol. 2015;21(8):2323\u201335.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2036_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.384","volume":"8","author":"S Zafar","year":"2017","unstructured":"Zafar S, et al. Cellular prion protein mediates early apoptotic proteome alternation and phospho-modification in human neuroblastoma cells. Cell Death Dis. 2017;8(1): e2557.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2036_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/1024533031000153630","volume":"8","author":"S Aref","year":"2003","unstructured":"Aref S, Goda T, El-Sherbiny M. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology. 2003;8(4):221\u20138.","journal-title":"Hematology"},{"issue":"12","key":"2036_CR19","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/sj.bjc.6604400","volume":"98","author":"D Loussouarn","year":"2008","unstructured":"Loussouarn D, et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008;98(12):1993\u20138.","journal-title":"Br J Cancer"},{"issue":"7","key":"2036_CR20","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/cncr.20542","volume":"101","author":"L Shah","year":"2004","unstructured":"Shah L, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004;101(7):1632\u20138.","journal-title":"Cancer"},{"issue":"7752","key":"2036_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1062-1","volume":"568","author":"W Yao","year":"2019","unstructured":"Yao W, et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019;568(7752):410\u20134.","journal-title":"Nature"},{"issue":"1","key":"2036_CR22","doi-asserted-by":"publisher","first-page":"C29","DOI":"10.1152\/ajpcell.00024.2022","volume":"323","author":"Z Yang","year":"2022","unstructured":"Yang Z, et al. Targeting syndecan-1: new opportunities in cancer therapy. Am J Physiol Cell Physiol. 2022;323(1):C29-c45.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"2036_CR23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/leu.2012.80","volume":"26","author":"N Hosen","year":"2012","unstructured":"Hosen N, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 2012;26(9):2135\u201341.","journal-title":"Leukemia"},{"issue":"6","key":"2036_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/leu.2011.373","volume":"26","author":"E Van Valckenborgh","year":"2012","unstructured":"Van Valckenborgh E, et al. Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia. 2012;26(6):1436\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"2036_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121(2):318\u201328.","journal-title":"Blood"},{"issue":"3","key":"2036_CR26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","volume":"41","author":"Y Kawano","year":"2012","unstructured":"Kawano Y, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876\u201384.","journal-title":"Int J Oncol"},{"issue":"38","key":"2036_CR27","doi-asserted-by":"publisher","first-page":"40496","DOI":"10.18632\/oncotarget.5800","volume":"6","author":"R Franqui-Machin","year":"2015","unstructured":"Franqui-Machin R, et al. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015;6(38):40496\u2013506.","journal-title":"Oncotarget"},{"issue":"1","key":"2036_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/ph16010111","volume":"16","author":"G Kozalak","year":"2023","unstructured":"Kozalak G, et al. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023;16(1):111.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"2036_CR29","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1073\/pnas.0611682104","volume":"104","author":"CD Peacock","year":"2007","unstructured":"Peacock CD, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007;104(10):4048\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2036_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.784983","volume":"9","author":"S Guo","year":"2021","unstructured":"Guo S, et al. The role and therapeutic value of syndecan-1 in cancer metastasis and drug resistance. Front Cell Dev Biol. 2021;9: 784983.","journal-title":"Front Cell Dev Biol"},{"key":"2036_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.matbio.2013.10.005","volume":"35","author":"VC Ramani","year":"2014","unstructured":"Ramani VC, Sanderson RD. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014;35:215\u201322.","journal-title":"Matrix Biol"},{"issue":"8","key":"2036_CR32","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1074\/jbc.M110.183277","volume":"286","author":"VC Ramani","year":"2011","unstructured":"Ramani VC, et al. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem. 2011;286(8):6490\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"2036_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.bbamcr.2014.11.019","volume":"1853","author":"D Wu","year":"2015","unstructured":"Wu D, et al. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1\/CXCR4\/AKT signaling pathway. Biochim Biophys Acta. 2015;1853(2):338\u201347.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2036_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-016-0579-2","volume":"16","author":"D Pradella","year":"2017","unstructured":"Pradella D, et al. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8.","journal-title":"Mol Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02036-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02036-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:03:55Z","timestamp":1741439035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02036-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2036"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02036-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}